Home  >  Research  >  Labs  >  Cancer Program  >  CELL SIGNALING


Our research focuses on a class of enzymes called protein tyrosine kinases (PTKs) and their involvement in cancer. These enzymes function as on/off switches that control many cellular functions, including cell growth, metabolism, differentiation, migration, invasion and metastasis. The Cell Signalling team is particularly interested in non-receptor PTKs of the Src Family Kinase (SFK) subfamily in malignant soft-tissue cancer (sarcoma), which includes bone, muscle, fat cell and connective tissue cancers. We are also interested in these enzymes (SFKs) and their control of red blood cell (RBC) quality and longevity, as high-quality blood transfusions are critical for many cancer patients. Indeed 1/3 of blood donations are used by cancer patients. While clinical trials of PTK inhibitors and other novel targeted therapies are readily achievable for the common cancers (e.g. breast and prostate), for sarcomas which are rare cancers (~1% of all cancers) clinical trials are very difficult to undertake. However, we are utilizing the power of next generation sequencing to undertake a personalized genomic medicine approach to identify sarcoma patients that have DNA/RNA signatures indicating they may respond to specific novel therapies.

Through our research we have developed expertise in manipulating proteins to define their function through partner identification, modified residues, domain/motif roles and subcellular localization. We have established several collaborations to make use of our technical expertise in other research areas including drug metabolism and cardiovascular disease.


Scientists find way to wipe a cell’s memory to better reprogram it as a stem cell

In a groundbreaking study published today in Nature, Australian scientists have resolved a long-standing problem in regenerative medicine. Led by Professor Ryan Lister from the Harry Perkins Institute of Medical Research and The University of Western Australia and Professor Jose M Polo from Monash University and the University of Adelaide,…

Read More

Perkins researcher elected as prestigious new Fellow

Professor Alistair Forrest from the Harry Perkins Institute of Medical Research has been selected alongside 27 new Fellows of the Australian Academy of Health and Medical Sciences. Professor Forrest is internationally regarded for his pioneering work, which has been driving forward our understanding of human diseases and the complex behaviour…

Read More

Molecular machines stop cancer’s clock

Head of the laboratory for Synthetic Biology and Drug Discovery, Professor Oliver Rackham, says cancer cells grow uncontrollably whereas normal cells limit their growth. “A normal cell grows for just the right amount of time that is required for us to develop and maintain our bodies. “They control their growth with…

Read More